Trial
NCT00655668
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
T-cell Non-Hodgkin's Lymphoma
Intervention
Lenalidomide
Why stopped
Decision not to pursue as single agent in the study population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-25